Richard Delorme is head of the Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders (InovAND) and head of the Department of Child and Adolescent Psychiatry at the Robert Debré Hospital, both in Paris, France. He has a broad background in child psychiatry and genetics, with expertise in the identification of biomarkers in rare diseases associated with autism. He is also a researcher at the Human Genetics and Cognitive Functions Laboratory at the Institut Pasteur, in Paris. In recent years, he has been involved in several research programs, brain imaging studies and IPSC-based drug screening technology. He is an author on more than 100 publications.
Richard Delorme
Head
Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders
From this contributor
Coronavirus tool kit may aid families with autistic children during lockdown
To help families cope with the sudden loss of professional support during the pandemic, one team in France has created a set of resources and information.
Coronavirus tool kit may aid families with autistic children during lockdown
By
Richard Delorme, Benjamin Landman
21 April 2020 | 4 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read